PCWG4 updates recommendations on treatment strategies and tumor characterization for prostate cancer, suggesting improved patient outcomes.
PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator-naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: